Long-Term Follow-Up of Patients Who Received Chemotherapy with S-1 and Docetaxel after Relatively Curative Surgery for Advanced Gastric Cancer Including Non-Curative Factors

• Published in: Gan to kagaku ryoho Vol. 47; no. 11; p. 1583
• Main Authors: Nemoto, Hiroshi, Tanaka, Kuniya
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.11.2020
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy, Adjuvant; Docetaxel - therapeutic use; Follow-Up Studies; Gastrectomy; Humans; Neoplasm Recurrence, Local; Patients; Stomach Neoplasms - drug therapy; Stomach Neoplasms - surgery
• ISSN: 0385-0684

There is no known recommended chemotherapy after radical surgery for gastric cancer for patients who have non-curative disease. We defined positive peritoneal cytology(CY1), resection margin involvement, pathological peritoneal metastasis (pP1)and pN3b as clinical non-curative factors and administered adjuvant chemotherapy with S-1 and docetaxel(DOC) (80 mg/m2 day 1-14 of S-1 for 2 weeks with 40 mg/m2 of DOC on day 1, every 3 weeks). This regimen lasted for 1 year; however, if chemotherapy could be continued after this period, we used S-1 only. We reported the results of 11 cases who received this treatment. There were 6 total gastrectomies and 5 distal gastrectomies. Clinical non-curative factors were 5 pP1, 5 pN3b, 3 CY1 and 1 resection margin involvement. At the end of adjuvant therapy there were 6 completions, 4 recurrences, and 1 patient with side effects. The main adverse event of Grade 3 or greater was neutropenia (46%). The recurrence rate was 63.6%. Types of relapse included 6 disseminations and 1 patient with lymph node involvement. One-, 3-, and 5-year survival rates were 100%, 72.7% and 72.7%, respectively, and the RFS was 64.0 months. S-1 and DOC adjuvant chemotherapy produced good results and may serve as a therapy of choice for patients with advanced gastric cancer with non-curative factors after a relatively curative resection.